Clinical Trial Update: Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pembrolizumab plus vibostolimab (MK-7684A) or atezolizumab in combination with chemotherapy as first-line treatment for extensive-sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)
• Tecentriq (atezolizumab) (atezolizumab)
• Vibostolimab (vibostolimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Small Cell Lung Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-30